4-(2-甲氧基-苯基)-噻唑-2-羧酸 | 952959-58-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(2-甲氧基-苯基)-噻唑-2-羧酸
• 英文名称: 4-(2-Methoxyphenyl)-1,3-thiazole-2-carboxylic acid
• CAS: 952959-58-9
• 化学式: C₁₁H₉NO₃S
• 分子量: 235.263
• InChiKey: FNGDFKSEPJEEOW-UHFFFAOYSA-N

物化性质

• 沸点：
  416.7±37.0 °C(Predicted)
• 密度：
  1.352±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-甲氧基-苯基)-噻唑-2-羧酸 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 4-(2-Methoxyphenyl)-1,3-thiazole
  参考文献：
  名称：

  Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors

  摘要：

  A series of novel 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides were investigated as dipeptidyl peptidase IV (DPP-4) inhibitors. Introduction of a 4-phenylthiazol-2-yl group showed highly potent DPP-4 inhibitory activity. Among various derivatives, (3R)-3-amino-N-(4-(4-phenylthiazol-2-yl)-tetrahydro-2H-thiopyran-4-yl)-4-(2,4,5-trifluorophenyl)butanamide 1,1-dioxide (30) reduced blood glucose excursion in an oral glucose tolerance test by oral administration. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.099
• 作为产物：
  描述：

  邻甲氧基-2-溴苯乙酮 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 4-(2-甲氧基-苯基)-噻唑-2-羧酸
  参考文献：
  名称：

  Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors

  摘要：

  A series of novel 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides were investigated as dipeptidyl peptidase IV (DPP-4) inhibitors. Introduction of a 4-phenylthiazol-2-yl group showed highly potent DPP-4 inhibitory activity. Among various derivatives, (3R)-3-amino-N-(4-(4-phenylthiazol-2-yl)-tetrahydro-2H-thiopyran-4-yl)-4-(2,4,5-trifluorophenyl)butanamide 1,1-dioxide (30) reduced blood glucose excursion in an oral glucose tolerance test by oral administration. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.099

文献信息

• PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS
  申请人：Schultz-Fademrecht Carsten

  公开号：US20140018365A1

  公开（公告）日：2014-01-16

  The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

  本发明涉及1-氮杂环-2-羧酰胺和/或其药学上可接受的盐，这些衍生物被用作药物活性剂，特别用于治疗和/或预防Axl受体酪氨酸激酶亚家族引起的疾病，包括癌症和原发性肿瘤转移，以及含有至少一种所述的1-氮杂环-2-羧酰胺衍生物和/或其药学上可接受的盐的制药组合物。
• Pharmaceutically active compounds as Axl inhibitors
  申请人：Schultz-Fademrecht Carsten

  公开号：US08999982B2

  公开（公告）日：2015-04-07

  The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

  本发明涉及1-氮杂环-2-羧酰胺和/或其药学上可接受的盐，这些衍生物的用途作为药物活性剂，特别是用于治疗和/或预防Axl受体酪氨酸激酶亚家族引起的疾病，包括癌症和原发性肿瘤转移，以及含有至少一种所述的1-氮杂环-2-羧酰胺衍生物和/或其药学上可接受的盐的制药组合物。
• US8999982B2
  申请人：——

  公开号：US8999982B2

  公开（公告）日：2015-04-07
• [EN] PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS<br/>[FR] COMPOSÉS PHARMACEUTIQUEMENT ACTIFS EN TANT QU'INHIBITEURS DE AXL
  申请人：LEAD DISCOVERY CENTER GMBH

  公开号：WO2012028332A1

  公开（公告）日：2012-03-08

  The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.